Journal of Drug Targeting · Nov 18, 2026
Engineered Extracellular Vesicles (EVs) as Carriers for CRISPR/Cas9 Therapeutics: Recent Advances in Cargo Loading and Targeted Delivery
By Zahid A, Ismail H, Qadeer A et al.
The therapeutic potential of CRISPR/Cas genome editing has advanced the development of precision medicine; however, its clinical translation for many in vivo applications remains limited by challenges in achieving safe, efficient, and targeted delivery. Conventional viral vectors and synthetic nanocarriers are associated with challenges including immunogenicity, limited cargo capacity, prolonged nuclease expression, off-target effects, and manufacturing complexities. Engineered extracellular vesicles (EVs) are being investigated as alternative delivery carriers due to their biological origin, capacity for cargo encapsulation, and opportunities for surface functionalization. However, their biocompatibility, immunogenicity, and ability to cross biological barriers depend on vesicle source, formulation, and experimental conditions. This review provides a comprehensive overview of recent advances in the design of engineered EVs for CRISPR/Cas delivery, with a particular focus on strategies to improve cargo loading, targeting specificity, and therapeutic efficacy. We discuss the advantages and limitations of different CRISPR cargo formats, including plasmid DNA, mRNA, and ribonucleoprotein complexes, together with endogenous and exogenous loading approaches, hybrid EV platforms, and methods for enhancing intracellular delivery. Advances in EV surface engineering through genetic, chemical, physical, and biomimetic modifications are highlighted as strategies being investigated to improve tissue-specific delivery and functional cargo transport. The review also highlights emerging research directions, including CRISPR-EV theranostic platforms and the application of artificial intelligence to enhance CRISPR-EV therapeutic systems. Finally, key translational challenges, including scalable production, EV heterogeneity, cargo-loading efficiency, biodistribution, regulatory standardization, and quality control, are critically discussed. EV-mediated CRISPR delivery remains at an early preclinical stage, with clinical safety and therapeutic efficacy yet to be established. Further advances in EV engineering, cargo-loading strategies, and manufacturing standardization are needed to support its potential clinical translation.
doi.org/10.1080/1061186x.2026.2764210PubMed 43049536Interventions